Published in Cancer Weekly, May 5th, 2009
"Sixty patients with previously untreated, measurable HER2-positive MBC (immunohistochemistry 3+ and/or fluorescence in situ hybridization positive) were treated with docetaxel 30 mg/m(2) intravenously (I.V.) and vinorelbine 25 mg/m(2) I.V on days 1 and 8 of each 3-week cycle. Trastuzumab was given weekly...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.